[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350273-105":59,"doc-detail-350273-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","mtap-loss-in-gastrointestinal-cancers-is-associated-with-cdkn2a-deletion-poor-prognosis-in-gastric-carcinoma-and-potential-relevance-for-prmt5-targeted-therapy","MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy","","Study evaluates how loss of MTAP across 1545 resected gastrointestinal tumors relates to CDKN2A status and overall survival. MTAP protein expression is assessed by immunohistochemistry and compared with CDKN2A using fluorescence in situ hybridization. MTAP loss co-occurs with homozygous CDKN2A deletion and is observed across cholangiocarcinoma, esophageal, gastric, and pancreatic cancers, with worse survival in gastric carcinoma. Results support MTAP loss as an independent prognostic factor and suggest a clinically actionable subgroup for PRMT5 inhibitor therapy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mtap-loss-in-gastrointestinal-cancers-is-associated-with-cdkn2a-deletion-poor-prognosis-in-gastric-carcinoma-and-potential-relevance-for-prmt5-targeted-therapy/350273/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mtap-loss-in-gastrointestinal-cancers-is-associated-with-cdkn2a-deletion-poor-prognosis-in-gastric-carcinoma-and-potential-relevance-for-prmt5-targeted-therapy/350273.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is MTAP loss in gastrointestinal cancers associated with?","Question",{"text":113,"@type":114},"MTAP loss consistently co-occurs with homozygous CDKN2A deletion across evaluated tumors.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does MTAP loss affect survival in gastric cancer patients?",{"text":118,"@type":114},"In gastric carcinoma, MTAP loss is associated with worse survival, including an even stronger association in patients undergoing primary surgery.",{"name":120,"@type":111,"acceptedAnswer":121},"Why might MTAP loss be relevant to PRMT5-targeted therapy?",{"text":122,"@type":114},"MTAP loss leads to MTA accumulation that inhibits PRMT5, and prior findings suggest increased sensitivity to PRMT5 inhibitors in cells with MTAP loss.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350273,1790193296,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy  \nSu Ir Lyu1,3􀀍, Karl Knipper2, Caroline Fretter1, EleniTzitzili2, Adrian Georg Simon1, HakanAlakus2, Aylin Pamuk2, ChristianeJ. Bruns2, Thomas Schmidt2, Felix C. Popp2 & Alexander Quaas1  \nGastrointestinal cancers account for a substantial share of global cancer burden. We assessed the significance of MTAP loss across 1545 resected tumors (cholangiocarcinoma, esophageal and gastric adenocarcinoma, pancreatic ductal adenocarcinoma). MTAP protein was evaluated by immunohistochemistry compared with CDKN2A status by fluorescence in situ hybridization and with overall survival. Immunohistochemical MTAP loss consistently co-occurred with homozygous CDKN2A deletion and was present in 25.5% of cholangiocarcinomas, 9.3% of esophageal adenocarcinomas, 10.3% of gastric carcinomas, and 30.2% of pancreatic adenocarcinomas. In gastric carcinomas, MTAP loss was associated with worse survival (p = 0.024), particularly in those who underwent primary surgery (p = 0.008). MTAP loss proved to be an independent factor for worse overall  \nsurvival in patients with gastric adenocarcinoma. 10% of esophageal adenocarcinomas showed intratumoral heterogeneity, but we did not see intertumoral heterogeneity between the primary tumor and corresponding lymph node metastases. These data indicate that a considerable subset of gastrointestinal cancers exhibits MTAP loss, highlight prognostic relevance in gastric carcinoma, and delineate a potentially actionable subgroup for PRMT5 inhibitor therapy.  \nKeywords MTAP-loss, Esophageal cancer, Gastric cancer, Pancreatic cancer, PRMT5-inhibitor  \nGastrointestinal cancers account for 26% of global cancer incidence and 35% of all cancer-related deaths worldwide-pancreatic cancer alone is among the most aggressive cancers with high mortality rates. With an expected increase in cancer mortality in the upcoming years, pancreatic cancer will likely surpass colorectal cancer deaths by 20401–3. Epidemiology varies between the distinct gastrointestinal malignancies, but overall, incidence and cancer-related deaths are expected to increase in the upcoming years3. Gastric cancer incidence has been declining in the past decades; however, it remains the 5th most frequently diagnosed cancer and the 3rd leading cause of cancer death worldwide3. Esophageal cancer represents the 7th most common cause of cancer morbidity and the 6th most common cause of cancer-related death worldwide3. Late diagnosis and advanced cancer stages at the time of diagnosis lead to poor prognosis, particularly among pancreatic and gastric cancers3. Meanwhile, cholangiocarcinoma is less common than the previously mentioned malignancies, only accounting for about 3% of cancers arising from the gastrointestinal tract, but the incidence is also steadily increasing4. A better understanding of tumor biology may enable the identification and targeting of distinct molecular pathways important for tumor survival.  \n5′-Methylthioadenosine phosphorylase (MTAP) is a key enzyme involved in polyamine metabolism andrecycles methylthioadenosine (MTA) to adenine and methionine, and salvages them5,6. MTAP loss has been observed in various cancer entities, including gastro-intestinal adenocarcinomas, neuroendocrine neoplasms,  \n1Faculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany. 2Faculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany. 3Institut für Allgemeine Pathologie und PathologischeAnatomie Uniklinik Köln, Kerpener Str. 62, 50937 Cologne, Germany. 􀀍 email: [su.lyu@uk-koeln.de](su.lyu@uk-koeln.de)  \nHodgkin lymphoma, mesothelioma, urothelial neoplasms, s","cbCaioeIVhLVaYn5","https://ap.wps.com/l/cbCaioeIVhLVaYn5","pdf",3096946,12,"English","# Introduction\n# Materials and methods\n## Patients and tumor samples","[{\"question\":\"What is MTAP loss in gastrointestinal cancers associated with?\",\"answer\":\"MTAP loss consistently co-occurs with homozygous CDKN2A deletion across evaluated tumors.\"},{\"question\":\"How does MTAP loss affect survival in gastric cancer patients?\",\"answer\":\"In gastric carcinoma, MTAP loss is associated with worse survival, including an even stronger association in patients undergoing primary surgery.\"},{\"question\":\"Why might MTAP loss be relevant to PRMT5-targeted therapy?\",\"answer\":\"MTAP loss leads to MTA accumulation that inhibits PRMT5, and prior findings suggest increased sensitivity to PRMT5 inhibitors in cells with MTAP loss.\"}]","MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy | PDF",1790088188,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b7304e68928bbb620f5080b085ed7a0.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3172b23d5aa27b6cbe1dbea76103a5d1.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/612a100b9b4073b06ef646d3abbe3900.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d5ac6cf877263e2f8d10ae42a7e6772.webp",980,1287]